Please login to the form below
acute myeloid leukemia
This page shows the latest acute myeloid leukemia news and features for those working in and with pharma, biotech and healthcare.
Astellas’ Xospata scores positive CHMP recommendation
The FLT3 inhibitor received the positive opinion for use as a monotherapy in the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation. ... 2017. AML is the most common form of acute leukaemia in adults and has a low
Latest news
-
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
UCART123 is a gene-edited CAR-T cell therapy that targets CD123 and will be tested in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
-
Pfizer's SMO inhibitor boosts survival in blood cancer trial
Glasdegib (previously known as PF-04449913) extended overall survival in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) to almost nine months when added to low-dose ... indications such as MDS, acute lymphoblastic
-
AbbVie and Roche's leukaemia drug venetoclax nears EU market
AbbVie and Roche believe that venetoclax will be effective across a range of blood cancers, and are testing the drug in acute myeloid leukemia, non-Hodgkin's lymphoma, and multiple myeloma
-
NICE rejects Celgene's Vidaza for leukaemia
The National Institute for Health and Care Excellence (NICE) has turned down Celgene's Vidaza to treat older people with acute myeloid leukemia (AML) in final draft guidance.
-
Baxalta’s rare blood cancer drug Oncaspar approved in Europe
First EU-wide licence for the acute lymphoblastic leukaemia treatment. Baxalta's aspirations in oncology have received a boost after the European Commission approved Oncaspar, its treatment for a rare form ... Baxalta also plans to investigate Oncaspar
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
Acute leukaemia patients get new online information centre that will help them get the best possible care
a-kind educational resource centre that provides acute leukaemia patients with the support they need, when they need it most. ... Some of the world's leading experts in the treatment of acute lymphoblastic leukaemia (ALL) and acute myeloid
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- How COVID-19 is accelerating the threat of antimicrobial resistance
- 20 for 2020 – Five pharma companies to watch
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- Using Artificial Intelligence to Transform Pharma
- Session 4: Systems Innovation Insight and Thinking
- Transforming Unstructured Healthcare Information into Real-World Evidence & Life Saving Insights
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Keytruda doubles five-year survival rate in NSCLC
- EMA fast-tracks review of bluebird bio’s LentiGlobin for sickle cell disease
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
